Jazz Pharmaceuticals PLC
JAZZ
查看详细走势图
165.500USD
+2.350+1.44%
收盘 02/06, 16:00（美东）报价延迟15分钟
10.05B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.44%
5天
+0.61%
1月
-2.28%
6月
+47.66%
今年开始到现在
-2.65%
1年
+37.58%
查看详细走势图
TradingKey Jazz Pharmaceuticals PLC股票评分
单位: USD 更新时间: 2026-02-06操作建议
Jazz Pharmaceuticals PLC当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名20/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价216.95。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Jazz Pharmaceuticals PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Jazz Pharmaceuticals PLC亮点
亮点风险
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
估值低估
公司最新PE估值-27.36，处于3年历史低位
机构减仓
最新机构持股62.93M股，环比减少12.50%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值106.37K
活跃度增加
近期活跃度增加，过去20天平均换手率0.17
分析师目标
根据
17
位分析师
买入
评级
216.954
目标均价
+30.92%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Jazz Pharmaceuticals PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Jazz Pharmaceuticals PLC简介
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
公司代码JAZZ
公司Jazz Pharmaceuticals PLC
CEOGala (Renee D)
网址https://www.jazzpharma.com/
相关品种
